Developing new drugs is a lengthy and expensive process, often requiring significant financial resources. Patent portfolio encourages BRIM to take on the risks associated with drug development by providing the potential incentive for licensing and collaboration. Moreover, patent portfolio provides protection against competitors who might try to create similar drugs or therapies.
After obtaining the global exclusive patent license from Mackay Hospital, this PDSP technology platform is intended to be used in dry eye disease (BRM421), neurotrophic keratitis (BRM424) and osteoarthritis (BRM521). To date, the related patent portfolio is comprised of 80 issued patents and 63 pending patent applications. Intellectual property rights include product derivatives, method of use, pharmaceutical formulations, and new indication.
Patents have been granted mainly in the US, Australia, Europe, Japan, South Korea, China, and Taiwan.
A total of 143 patents globally, out of which 63 have been granted. Update date: 2024.06.30
| Patent application status | |||
| Country area | Granted | Pending | Total |
|---|---|---|---|
| Asian countries
(Taiwan, China, Japan, South Korea, |
30 | 38 | 144 |
| American countries
(United States, Brazil, Canada, Mexico) |
11 | 10 | |
| European countries
(EU, Germany, UK, Ireland, France, |
34 | 6 | |
| Oceania countries
(Australia, New Zealand) |
6 | 5 | |
| Patent Cooperation Treaty Organization (PCT) | — | 4 | |
